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ATF4 Is a Substrate of RSK2 and an Essential
Regulator of Osteoblast Biology:
Implication for Coffin-Lowry Syndrome
campomelic or cleidocranial dysplasia, the diseases
caused by Sox9 or Runx2 haploinsufficiency. Such
milder phenotypes imply that the genes mutated in these
diseases may act later during skeletogenesis than Sox9
or Runx2. One skeletal dysplasia inherited in a dominant
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and Bone Disease Program of Texas with delayed bone age, delayed closure of fontanelles,
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Houston, Texas 77030 The gene mutated in CLS, RSK2, encodes a growth
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et Cellulaire ribosomal serine/threonine kinases that contain two dis-
tinct kinase domains, one at the C-terminal and one atC.U. de Strasbourg
67404 Illkirch Cedex the N-terminal (Trivier et al., 1996; Xing et al., 1996;
Frodin et al., 2000). ERK phosphorylation of RSK2 C-ter-France
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kinase domain, which can then phosphorylate its sub-Genetics
University of Alabama at Birmingham strates (Fisher and Blenis, 1996; Dalby et al., 1998). In
vitro, RSK2 phosphorylates CREB and is required forBirmingham, Alabama 35294
growth-factor-stimulated transcription of c-Fos (Xing et
al., 1996; Bruning et al., 2000). CREB phosphorylation,
however, is not altered and c-Fos expression increasesSummary
normally following exercise in Rsk2-deficient mice (Du-
fresne et al., 2001) suggesting that RSK2 has other sub-Coffin-Lowry Syndrome (CLS) is an X-linked mental
retardation condition associated with skeletal abnor- strates.
Besides molecular elucidation of human skeletal dys-malities. The gene mutated in CLS, RSK2, encodes a
growth factor-regulated kinase. However, the cellular plasias other experimental approaches have been used
with great success to improve our understanding of celland molecular bases of the skeletal abnormalities as-
sociated with CLS remain unknown. Here, we show differentiation during skeletogenesis. One of them is the
analysis of regulatory sequences in cell-specific genesthat RSK2 is required for osteoblast differentiation and
function. We identify the transcription factor ATF4 as followed by verification of findings generated by these
studies through mouse genetics. This also led for in-a critical substrate of RSK2 that is required for the
timely onset of osteoblast differentiation, for terminal stance to the identification of Runx2 as an osteoblast
differentiation factor (Ducy et al., 1997).differentiation of osteoblasts, and for osteoblast-spe-
cific gene expression. Additionally, RSK2 and ATF4 Using a combination of human genetic information,
analysis of mutant mouse strains, and molecular stud-posttranscriptionally regulate the synthesis of Type
I collagen, the main constituent of the bone matrix. ies, we show here that RSK2 is required for osteoblast
differentiation and function in vivo and provide molecu-Accordingly, Atf4-deficiency results in delayed bone
formation during embryonic development and low lar and genetic evidence that ATF4 is a substrate of
RSK2 in osteoblasts. We also show that ATF4 regulatesbone mass throughout postnatal life. These findings
identify ATF4 as a critical regulator of osteoblast differ- several aspects of osteoblast biology ranging from on-
set of differentiation to cell-specific gene expression.entiation and function, and indicate that lack of ATF4
phosphorylation by RSK2 may contribute to the skele- Moreover, ATF4 and RSK2 regulate Type I collagen syn-
thesis through a posttranscriptional mechanism. Thesetal phenotype of CLS.
findings identify ATF4 as a critical regulator of osteoblast
differentiation and function, and indicate that lack ofIntroduction
ATF4 phosphorylation by RSK2 may contribute to the
skeletal phenotype of CLS.An efficient means to identify transcription factors de-
termining skeletal cell differentiation has been the mo-
lecular elucidation of human skeletal dysplasias with Results
a dominant mode of inheritance. This contributed, for
instance, to the identification of Sox9 and Runx2 as Decreased Bone Mass in Rsk2-Deficient Mice
initiators of chondrocyte and osteoblast differentiation, Based on Rsk2 expression in osteoblasts and on the
respectively (Kwok et al., 1995; Lee et al., 1997; Mundlos existence of skeletal abnormalities in CLS patients, we
et al., 1997). Other skeletal dysplasias that are inherited generated and analyzed Rsk2-deficient mice. The muta-
either in a recessive manner or in a dominant manner tion engineered was a null allele that did not affect syn-
with reduced penetrance have a milder phenotype than thesis of other RSKs (Figures 1A–1E). Rsk2-deficient
mice were born at the expected Mendelian ratio, had a
normal lifespan, and no histological or metabolic evi-*Correspondence: karsenty@bcm.tmc.edu
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Figure 1. Decreased Bone Mass in Rsk2-Deficient Mice
(A) Northern analysis showing Rsk2 expression in osteoblasts.
(B) Generation of Rsk2-deficient mice. Arrows, PCR primers used to distinguish mutant from wild-type (wt) loci; Asterisks, stop codons; Red
bar, 3 external probe; B, BamHI; Bs, BasRI; X, XbaI; and S, SacI.
(C) Southern blot analysis of indicated genotypes using the 3 external probe. Fragments, wt, 9 kb; mutant, 11 kb.
(D) PCR genotyping. wt and targeted alleles yield 230 bp and 320 bp products, respectively.
(E) Western blot analysis showing absence of RSK2 but presence of RSK1 and RSK3 in Rsk2-deficient cells. ERK1/2 was a loading control.
(F) Alizarin red/alcian blue staining of E16 and P0 skeletons. Frontal, parietal, and interparietal bones (arrowheads) are smaller and fontanelles
are not closed (bottom) in Rsk2-deficient embryos and mice.
(G) Decreased long bone length in Rsk2-deficient mice.
(H) Histological analysis of one-month old wt and Rsk2-deficient vertebrae. Mineralized bone matrix is stained in black. The ratio of bone
volume (BV) versus total tissue volume (TV) is decreased in Rsk2-deficient mice.
(I) Calcein double labeling of one-month old wt and Rsk2-deficient vertebrae. Bone formation rate (BFR) is decreased in Rsk2-deficient mice.
Asterisks indicate a statistically significant difference between 2 groups (p  0.05).
dence of internal organs dysfunction (see Supplemental number and thickness of trabeculae were markedly de-
creased in Rsk2-deficient mice (Figures 1H and 1I). InFigure S1 available at http://www.cell.com/cgi/content/
full/117/2/387/DC1). Nevertheless, analysis of skeletal contrast, osteoclast number and urinary elimination of
deoxypyridinoline, a biochemical marker of osteoclastpreparations stained with alizarin red for mineralized
tissue and alcian blue for cartilage revealed that at E16 activity, were both normal in Rsk2-deficient mice indi-
cating that bone resorption is not overtly affected inand at birth Rsk2-deficient embryos and pups of either
sex had a delay in mineralization of the skull with frontal, absence of Rsk2 (data not shown). Together these re-
sults reveal the existence of a low bone mass phenotypeparietal, and interparietal bones of reduced size. This
resulted in a widening of cranial sutures and opened secondary to a decrease in bone formation in Rsk2-
deficient mice.fontanelles at birth (Figure 1F). Rsk2-deficient mice also
had a significant reduction in long bone length at one
month of age (Figure 1G). These abnormalities are simi- ATF4 Is a Substrate of RSK2 in Osteoblasts
We next asked whether RSK2 phosphorylates transcrip-lar to those reported in CLS patients (Young, 1988; Tri-
vier et al., 1996). tion factors that may control osteogenesis. Since RSK2
can phosphorylate CREB and c-Fos, two leucine zipperHistological analysis revealed that Rsk2-deficient
mice of either sex had a marked reduction of their bone proteins, we used these proteins as positive controls in
an in vitro kinase assay and analyzed multiple othermass in vertebrae and in long bones at one and two
month age (Figure 1H and data not shown). Histomor- leucine zipper proteins as well as Runx2 and Osterix,
two transcription factors necessary for osteoblast differ-phometric analysis established that the bone formation
rate (BFR), an indicator of osteoblast function, and the entiation (Karsenty and Wagner, 2002). As shown in Fig-
ATF4 and RSK2 Control Bone Formation
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Figure 2. ATF4 Is a Substrate of RSK2 in Osteoblasts
(A) In vitro kinase assays using recombinant proteins. ATF4 is the most heavily phosphorylated protein by RSK2 (top). Asterisks indicate
protein input (bottom).
(B) Western blot analysis. ATF4 migrates as a doublet in osteoblast nuclear extracts (NE), the slower migrating band disappears following
calf intestinal phosphatase (CIP) treatment.
(C) RSK2 interacts with ATF4 in osteoblasts. Immunoprecipitation of osteoblast NE followed by immunoblotting with either ATF4 or RSK2
antibodies. Controls, NE incubated with Protein G Sepharose alone (beads) or with nonrelated antibodies (anti-Runx2 or anti-HA). SP1 antibody
serves as a loading control.
(D) Mapping of RSK2 phosphorylation site in ATF4. ATF4 deletion mutant 186–249 and peptide 244–258 (lane 12) are both phosphorylated
by RSK2. Substitution of serine 251 to alanine abolishes this phosphorylation (asterisk, lane 13).
(E) In vitro kinase assays of His-tagged wt ATF4 or mutant ATF4 proteins. Phosphorylation of ATF4-S251A, -251D, or -251R by RSK2 is
markedly decreased.
(F) Mapping of RSK2 phosphorylation site to serine 245 in human ATF4. Mutating serine to alanine abolishes phosphorylation in peptide
242–250 (asterisk, lane 7) and in human ATF4.
(G) Location of RSK2 phosphorylation sites in mouse and human ATF4. The basic (b) and leucine zipper (ZIP) domains are boxed.
(H) In vivo phosphorylation of ATF4 is decreased in Rsk2-deficient osteoblasts. Probing with an anti-ATF4 antibody indicating the same
amounts of ATF4 was used (bottom).
(I) Antiphospho-ATF4 fails to recognize ATF4 following CIP treatment of osteoblast NE (lane 2, top). Phosphorylation of ATF4-S251 is abolished
in Rsk2-deficient osteoblasts (lane 3, top). ATF4 and Sp1 antibodies were used to monitor protein loading. ATF4 migrates as a doublet as it
is phosphorylated by other kinases.
(J) ATF4 phosphorylation in wt but not in Rsk2-deficient osteoblasts following TPA treatment. Antiphospho-RSK2 and anti-RSK2 were used
as controls (left).
ure 2A, among all proteins tested ATF4 was heavily deletion mutants and synthetic peptides covering the
ATF4 molecule. Only ATF4 deletion mutant encom-phosphorylated, while Runx2 and Osterix were not
phosphorylated by RSK2. Based on this observation, passing amino acids 186–349 and one internal peptide
(244–258) were phosphorylated by RSK2 (Figure 2D).we investigated the mechanism by which RSK2 may
phosphorylate ATF4 in osteoblasts. Out of three serine residues contained in this peptide
only substitution of serine 251 to alanine, aspartic acid,In osteoblasts, nuclear extracts ATF4 migrated as a
doublet and treatment of nuclear extracts with calf intes- or arginine nearly abolished ATF4 phosphorylation by
RSK2 (Figure 2E). In vitro kinase assay using peptidestinal phosphatase prevented the formation of the slower
migrating band indicating that it is a phosphorylated covering regions of human ATF4 that differs from its
mouse-homolog-identified sequence from amino acidform of ATF4 (Figure 2B). Moreover, an ATF4 antibody
precipitated RSK2 present in osteoblast nuclear ex- 242–250 as being phosphorylated by RSK2 and mutation
of serine 245 to alanine decreased phosphorylation oftracts and conversely a RSK2 antibody precipitated
ATF4 thus showing that endogenous RSK2 and ATF4 human ATF4 by RSK2 (Figures 2F and 2G) indicating that
it is a site of phosphorylation of human ATF4 by RSK2.are able to interact physically (Figure 2C). To identify
the amino acid residues in ATF4 phosphorylated by To ascertain that RSK2 phosphorylates ATF4 in vivo
we used wt and Rsk2-deficient osteoblasts. ATF4 immu-RSK2 we performed in vitro kinase assays using ATF4
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noprecipitation experiments using metabolically labeled beculae in Atf4-deficient long bones while they re-
mained rare, short, and markedly thinner compared towt and Rsk2-deficient osteoblast nuclear extracts
showed that 32P incorporation into ATF4 was decreased wt ones (Figure 3B, m, n, q, r, u, and v).
There was also molecular evidence of a delay in osteo-in Rsk2-deficient cells (Figure 2H). Furthermore, an ATF4
(S251) phosphospecific antibody reacted with ATF4 in blast differentiation in absence of Atf4. For instance,
expression of Bone Sialoprotein (Bsp), a molecularwt but not in Rsk2-deficient osteoblasts. The identity of
this band as being phosphorylated ATF4 was estab- marker of differentiated osteoblasts (Aubin and Triffitt,
2002), was undetectable in E15 and E16 Atf4-deficientlished by reprobing the same blot with an antibody rec-
ognizing all forms of ATF4 (Figure 2I). Lastly, when wt skulls and long bones and much weaker in newborn
Atf4-deficient skulls (Figure 3B, c, d, g, h, k, l, o, p, s, t,and Rsk2-deficient osteoblasts were treated with TPA,
an inducer of RSK2 phosphorylation (Merienne et al., w, and x). Likewise, expression of Osteocalcin, the latest
marker of differentiated osteoblasts to appear (Aubin2000), phosphorylation of ATF4 was increased in wt but
not in Rsk2-deficient osteoblasts (Figure 2J). Taken to- and Triffitt, 2002), was decreased in E16 Atf4-deficient
embryos and newborn mice compared to wt littermatesgether, these results support the hypothesis that ATF4
is a target of RSK2 kinase activity in osteoblasts in vivo. (Figure 3C, a–d). In contrast, expression of genes char-
acteristic of earlier stages of osteoblast differentiationThis was further tested using several mutant mouse
models (see Figure 7). was not affected by Atf4 inactivation. Indeed, Runx2
and Osterix (Figure 3C, e–l), two transcription factors
required for differentiation of mesenchymal cells intoATF4 Is Required for Osteoblast Differentiation
osteoblasts, and 1(I) Collagen (Figure 3C, m–p), wereThe phosphorylation of ATF4 by RSK2 in vivo and the
all normally expressed in absence of Atf4. Together,skeletal abnormalities of the Rsk2-deficient mice sug-
these histological and molecular observations demon-gested that ATF4 might regulate osteogenesis. That
strate that ATF4 is required for the timely onset and forAtf4-deficient mice often die perinatally and are runted
terminal differentiation of osteoblasts.is compatible with this hypothesis (Tanaka et al., 1998;
To ascertain that Atf4 expression was compatible withHettmann et al., 2000; Masuoka and Townes, 2002).
its role during skeletal development, we studied its ex-Thus, wt and Atf4-deficient embryos and mice were
pression in E16 wt embryos. Consistent with its functionanalyzed by skeletal preparations, histology, and osteo-
during fetal liver hematopoiesis, Atf4 was highly ex-blast-specific gene expression.
pressed in liver; however, skeleton was the second high-Alizarin red/alcian blue staining of skeletal prepara-
est site of Atf4 expression. In the skeleton, Atf4 expres-tions of E14 and E16 embryos showed a marked reduc-
sion was present in osteoblasts and was markedlytion in the area of mineralized tissues in Atf4-deficient
reduced in cells occupying E16 Runx2-deficient skeletalcompared to wt embryos. This defect was observed in
elements indicating that Atf4 expression in osteoblastsfrontal and parietal bones, two bones also affected by
is dependent on Runx2 expression (Figures 3D and 3E).Rsk2 deletion (see Figure 1), and in clavicles and long
Consistent with this hypothesis there is a bona fidebones. At birth, the delay of mineralization in the skull
Runx2 binding site in the Atf4 promoter (Figures 3Fwas still present as shown by widening of the fontanelles
and 3G).(Figure 3A). At all stages analyzed, Atf4/ mice looked
indistinguishable from wt littermates (data not shown).
Histological analysis revealed no difference between Osteocalcin Is a Target Gene of ATF4 In Vivo
The decreased Osteocalcin expression in Atf4-deficientwt and Atf4-deficient skeletal elements in E13 or
younger embryos indicating that ATF4 was dispensable embryos suggested that this gene may be a target of
ATF4. Two osteoblast-specific cis-acting elements arefor early stages of skeletogenesis (Supplemental Figure
S2 available on Cell website). In contrast, a noticeable present in the Osteocalcin promoter (Ducy and Karsenty,
1995). One of them is the binding site for Runx2 whiledelay in osteoblast differentiation was observed
throughout the skeleton in E15 Atf4-deficient embryos. OSE1, binds an osteoblast-specific nuclear protein that
has been partially purified (Schinke and Karsenty, 1999)For instance, trabeculae were absent in Atf4-deficient
frontal bones while they were already present in wt (Figure 4A). Several lines of evidence indicate that this
OSE1 binding protein and ATF4 are indistinguishable.skulls. In E16, Atf4-deficient skulls trabeculae were
short, thin, and rare while in wt skulls they were long, First, OSE1 sequence has homology with a CREB/
ATF binding site and purified OSE1 binding protein stillthick, and numerous. At birth, trabeculae in Atf4-defi-
cient skulls remained strikingly thinner than in wt skulls bound DNA after boiling (Figures 4A and 4B), a hallmark
of leucine zipper-containing transcription factors(Figure 3B, a, b, e, f, i, and j). This peculiar thinning
of trabeculae provides a plausible explanation for the (McKnight, 1992). Second, ATF4 bound to wt OSE1 but
not to mutated forms of OSE1 to which OSE1 bindingperinatal lethality of Atf4-deficient mice as the brain
is poorly protected during delivery. The same delay in protein could not bind either and no other leucine zipper
proteins tested had the same binding profile (Figureappearance of bone existed in Atf4-deficient appendicu-
lar skeleton. In E15, wt embryos a bone collar sur- 4C). Third, only antibodies directed against ATF4 could
supershift or inhibit binding of osteoblast nuclear ex-rounding the future long bones was visible and trabecu-
lae were present, in contrast there was no morphological tracts to OSE1 (Figure 4D and Supplemental Figure S3A
available on Cell website). Fourth, the OSE1 bindingevidence of trabeculae or of a bone collar in E15 Atf4-
deficient long bones. In E16, wt long bones numerous activity present in wt nuclear extracts was absent in
Atf4-deficient osteoblast nuclear extracts (Figure 4E).trabeculae were present while none could be found in
Atf4-deficient long bones. At birth there were some tra- Fifth, in chromatin immunoprecipitation (ChIP) assay an
ATF4 and RSK2 Control Bone Formation
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Figure 3. Delayed Skeletal Development in Absence of Atf4
(A) Alcian blue/alizarin red staining of E14, E16, and P0 wt and Atf4-deficient skeletons. Note the lack of alizarin red staining in skull, clavicles
(E14 and E16), and limbs (E14) in Atf4-deficient embryos and the widening of fontanelles in Atf4-deficient newborn mice (arrowhead).
(B) H&E staining of wt (a, e, i, m, q, and u) and Atf4-deficient (b, f, j, n, r, and v) embryos and mice at E15 (a, b, m, and n), E16 (e, f, q, and r)
and P0 (i, j, u, and v). Note the delay in bone formation in Atf4-deficient skulls (a, b, e, f, i, and j) and long bones (m, n, q, r, u, and v) at all
stages. In situ hybridization of wt (c, g, k, o, s, and w) and Atf4-deficient (d, h, l, p, t, and x) skulls (c, d, g, h, k, and l) and limbs (o, p, s, t, w,
and x) using Bsp as a probe. Bsp expression is absent in E15 and E16 Atf4-deficient skulls and markedly reduced in P0 Atf4-deficient skulls.
It is also decreased in Atf4-deficient limbs compared to wt controls at all time points analyzed. Magnification: 100.
(C) In situ hybridization analysis of wt (a, c, e, g, i, k, m, and o) and Atf4-deficient long bones (b, d, f, h, j, l, n, and p), E16 (a, b, e, f, i, j, m,
and n) embryos, and P0 mice (c, d, g, h, k, l, o, and p). Probes are: Osteocalcin (a–d), Runx2 (e–h), Osterix (i–l), and a1(I) Collagen (m–p). Only
Osteocalcin expression is decreased in Atf4-deficient bones at all stages analyzed. Magnification: 50.
(D) Atf4 expression in skeleton of E16 wt embryos. Magnification: 25.
(E) Atf4 expression is reduced in E16 Runx2-deficient bones (b) compared to wt (a) littermates. Magnification: 100.
(F) Electrophoresis mobility shift assay (EMSA). Runx2 binds to an OSE2 site present in Atf4 promoter (OSEATF4, solid arrowhead). Runx2
antibody supershifts this protein-DNA complex (empty arrowhead).
(G) EMSA. Increasing amount of specific (OSE2OG2) but not of nonspecific (OSE1OG2) cold competitors at 0, 50, 100, and 200 excess of
radiolabeled probe (triangles) inhibits binding of Runx2 to OSE2ATF4.
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Figure 4. Osteocalcin Is a Target Gene of
ATF4
(A) Osteocalcin promoter (OG2) showing
OSE2 (Runx2 binding site) and OSE1 (ATF4
binding site).
(B) EMSA. Purified OSE1 binding protein still
binds to OSE1 after boiling.
(C) Binding of indicated leucine zipper pro-
teins to wt or mutant OSE1 oligonucleotides.
Only ATF4 behaves like OSE1 binding protein.
(D) Only ATF4 antibodies supershifted (empty
arrowhead, lane 2) or prevented formation
(solid arrowhead, lane 3) of nuclear extracts-
OSE1 complex.
(E) EMSA. Absence of binding activity to
OSE1 in Atf4-deficient osteoblast nuclear ex-
tracts. Runx2 binding to OSE2 (lanes 5 and
6) was used as a control of nuclear extract
quality.
(F) ChIP analysis. ATF4 binds to the Osteocal-
cin promoter (OG2) but not to its coding re-
gion (E IV) or to the Runx2 promoter (Runx2).
Runx2 and C/EBP antibodies were used as
positive and negative controls, respectively
(Ducy et al., 1999).
(G) DNA cotransfection using wt or mutant
pOG2-luc reporter and expression vectors of
ATF4 and indicated proteins in COS cells.
Fold activations are shown. Western blot
(bottom) shows the presence of ATF4 in
transfected cells.
(H) DNA cotransfection assays showing
specificity of ATF4 function. Western blot
(bottom) verified expression of proteins
tested.
ATF4 antibody precipitated the Osteocalcin promoter, and thickness of trabeculae in Atf4-deficient bones. As
a result Atf4-deficient mice failed to ever reach a normalas did an antibody against Runx2, a known regulator of
Osteocalcin (Ducy et al., 1997). These immunoprecipita- bone mass indicating that ATF4 is required for bone
mass accrual (Figures 5A and 5B). This phenotype wastions were specific since ATF4 antibody could not pre-
cipitate Osteocalcin coding region or an unrelated pro- due in part to a failure to achieve terminal differentiation
of osteoblasts as shown by the 2-fold decrease in Osteo-moter (Runx2 promoter). Moreover, an antibody against
another leucine zipper protein failed to precipitate this calcin expression in Atf4-deficient bones (Figure 5C).
This was also due to a defect in osteoblast function asOsteocalcin promoter fragment (Figure 4F). Lastly, in
DNA cotransfection experiments, an Atf4 expression shown by a 2-fold decrease in the rate of bone formation
in adult Atf4-deficient bones (Figure 5D). Thus, the bonevector increased activity of an Osteocalcin promoter-
luciferase chimeric gene (pOG2-luc) 5-fold. A mutation phenotype of adult Atf4-deficient mice is similar to the
one observed in Rsk2-deficient mice. Atf4-deficientabolishing Runx2 binding to OSE2 in this promoter frag-
ment did not affect ATF4 transactivation ability while a mice bone phenotype was also reminiscent of the one
seen in mice lacking LRP5 (Kato et al., 2002), however,mutation eliminating binding of nuclear proteins to OSE1
did (Figure 4G). Again, none of the leucine zipper pro- ATF4 was present in Lrp5-deficient osteoblast nuclear
extracts (Supplemental Figure S4 available on Cellteins tested, even members of the CREB family, trans-
activated pOG2-luc (Figure 4H and Supplemental Figure website).
S3B available on Cell website). These findings along
with the decrease in Osteocalcin expression observed in Decrease Type I Collagen Synthesis in Absence
of ATF4Atf4-deficient mice indicate that Osteocalcin is a target
gene of ATF4 in vivo. Bone trabeculae were abnormally thin in absence of
Atf4 and Atf4-deficient osteoblasts were considerably
smaller than wt osteoblasts (Figure 6A). This small cellATF4 Controls Bone Mass Postnatally
That a significant number of Atf4-deficient mice lived size was not observed in bone marrow cells or in osteo-
clasts indicating that Atf4 inactivation did not cause abeyond birth allowed us also to determine whether ATF4
is required for bone homeostasis postnatally. Histologi- general defect of cell size (Figures 6A and 6B). This
raised the hypothesis that a defect in protein synthesiscal analysis at multiple time points over a year showed
a severe reduction in bone volume and in the number may exist in Atf4-deficient osteoblasts. To test this hy-
ATF4 and RSK2 Control Bone Formation
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Figure 5. Low Bone Mass in Atf4-Deficient Mice
(A) Histomorphometric analysis of two-month-old wt and Atf4-deficient vertebrae. Note the decrease in bone volume (BV/TV), trabeculae
number (TbN), and trabecular thickness (TbTh) in Atf4-deficient mice.
(B) Atf4-deficient mice fail to acquire a normal bone mass postnatally.
(C) Decreased Osteocalcin expression in Atf4-deficient bones.
(D) Decreased BFR in two-month-old Atf4-deficient mice.
pothesis, we examined synthesis of Type I collagen, the collagen fibrils, we noticed a dramatic decrease of colla-
gen content in E16 Atf4-deficient compared to wt ormain biosynthetic product of osteoblasts, in wt and Atf4-
deficient osteoblasts. heterozygous tibia (Figure 6C). When cultured in ab-
sence of nonessential amino acids, Type I collagen syn-Using van Gieson reagent, which stains specifically
Figure 6. ATF4 Is Required for Type I Colla-
gen Synthesis in Osteoblasts
(A) Toluidine blue staining of one-month-old
vertebrae. Atf4-deficient osteoblasts are
smaller than wt (arrowheads) whereas bone
marrow cells are of similar size (400).
(B) TRAP-staining of one-month-old verte-
brae. Osteoclast size is similar in Atf4-defi-
cient bones (400).
(C) van Gieson staining of wt, Atf4/, and
Atf4/ E16 tibia. Reduced number of van
Gieson-stained collagen-rich trabeculae in
Atf4-deficient tibia (arrowheads). Magnifica-
tion: 100.
(D) Type I collagen synthesis analysis. Syn-
thesis of both 1 and 2 chains of Type I
collagen are decreased in Atf4-deficient os-
teoblasts; addition of nonessential amino
acids (NEAA) to cultures rescues this defect.
Histogram shows the percentage of 35S-
Methionine/Cystein incorporation into both
1 and 2 chains of Type I collagen relative
to -actin control (n  3).
(E) Normal 1(I) Collagen expression in Atf4-
deficient osteoblasts.
(F) Normal abundance of Runx2 and Osterix




Figure 7. Genetic Interaction between RSK2 and ATF4
(A) van Gieson staining of E16 female wt, Rsk2/ and Rsk2/ tibia showing decreased collagen content only in Rsk2/ limbs (100).
(B) Decreased Type I collagen synthesis in Rsk2-deficient osteoblasts.
(C) Normal expression of 1(I) Collagen in Rsk2-deficient osteoblasts.
(D) Decreased expression of Bsp in E16 Rsk2-deficient bones.
(E) Decreased expression of Osteocalcin in Rsk2-deficient osteoblasts.
(F) Expression of wt Rsk2 allele in heterozygous mutant mice by real-time reverse transcriptase-PCR.
(G) Decreased long bone length (left), bone mass (middle) and bone formation rate (right) in 1-month Atf4/; Rsk2/ female mice.
(H) Decreased Type I collagen synthesis in Atf4/; Rsk2/ osteoblasts.
(I) RSK2 increases OG2 promoter activity through OSE1. RSK2 expression was confirmed by Western blot. Sp1 serves as a loading control
(bottom).
(J) RSK2 enhances ATF4 transcriptional ability. DNA cotransfection assays using p6OSE1-Luc as a reporter vector (200 ng) and RSK2-T707A
(10 ng), ATF4 (25 ng) or ATF4-S251A (25 ng) as expression vectors. RSK2-T707A doubled the transactivation activity of wt ATF4 but not of
ATF4-S251A. Western blot verified the presence of RSK2 and ATF4 proteins.
thesis was decreased 7–10-fold in Atf4-deficient but not of ATF4 in Rsk2-deficient osteoblasts implied that RSK2
and ATF4 act in a linear cascade controlling osteoblastin wt osteoblasts. Addition of nonessential amino acids
in culture medium corrected the defect in collagen syn- differentiation and function. If this is the case, cellular
and molecular abnormalities present in Atf4-deficientthesis in osteoblasts lacking ATF4 (Figure 6D). This de-
crease in Type I collagen synthesis was not due to a mice should be present in Rsk2-deficient mice. Addition-
ally Rsk2/; Atf4/ mice may have phenotypic anddecrease of gene expression as 1(I) Collagen expres-
sion was identical in wt and mutant osteoblasts (Figure cellular abnormalities similar to the ones seen in Rsk2-
and Atf4-deficient mice.6E). Likewise, Runx2 and Osterix were present in normal
abundance in Atf4-deficient osteoblasts (Figure 6F). To test the first hypothesis, we measured Type I colla-
gen synthesis in Rsk2-deficient female mice as posttran-This result indicates that the decrease in Type I collagen
synthesis observed in Atf4-deficient osteoblasts is sec- scriptional decrease of Type I collagen synthesis is a char-
acteristic feature of Atf4-deficient mice. As shown in Figureondary to a decrease in amino acid import, a function
regulated by ATF4 in other cell types (Harding et al., 1H, trabeculae were thinner and van Gieson staining
showed a marked decrease in collagen abundance in2003). It also establishes that part of the skeletal pheno-
type observed in absence of Atf4 can be attributed to bones lacking Rsk2 (Figure 7A). Consistent with this
histological finding, Type I collagen synthesis was de-a posttranscriptional defect.
creased in Rsk2-deficient osteoblasts while (I) collagen
expression was not (Figures 7B and 7C). This posttran-RSK2 Interacts with and Modulates
Transactivation Function of ATF4 scriptional alteration of Type I collagen synthesis linked
together the phenotypes of Rsk2- and of Atf4-deficientThe similarity in the bone phenotypes caused by either
Rsk2 or Atf4 inactivation and the lack of phosphorylation mice and also showed that the defect in Rsk2-deficient
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osteoblasts was, at least in part, cell autonomous. In ing CREB, c-Fos, and estrogen receptor (ER) (Xing et
addition, Bsp and Osteocalcin, two genes whose ex- al., 1996; De Cesare et al., 1998; Joel et al., 1998; Bruning
pression was decreased in Atf4-deficient embryos and et al., 2000). However, c-Fos or Er inactivation in mice
osteoblasts, were also expressed at low levels in Rsk2- do not cause a bone phenotype similar to the one ob-
deficient bones and osteoblasts, respectively (Figures served in Rsk2-deficient mice (Johnson et al., 1992;
7D and 7E). To test the second hypothesis, we generated Wang et al., 1992; Sims et al., 2002). Our in vitro kinase
female mice lacking one copy of Atf4 and one copy of assay identifies ATF4 as an additional target of RSK2.
Rsk2 and analyzed them at one month of age. Since ATF4 and RSK2 interact physically and serines 251 and
Rsk2 does not escape X-inactivation, Rsk2/ female 245 in mouse and human ATF4 respectively are phos-
mice are mosaic and express also the wt allele (Figure phorylated by RSK2. Several lines of evidence support
7F). Rsk2/; Atf4/ mice had shorter long bones and the contention that ATF4 is a substrate of RSK2 in osteo-
histological analysis showed a lower bone mass and blasts in vivo. First, 32P incorporation into ATF4 is re-
decreased bone formation rate compared to single het- duced in Rsk2-deficient cells; second, a phosphoanti-
erozygous littermates (Figure 7G). Type I collagen pro- body directed toward serine 251 failed to detect ATF4
duction was also decreased in Rsk2/; Atf4/ osteo- in Rsk2-deficient osteoblasts; third, the same cellular
blasts but its expression was not (Figure 7H). (decrease in Type I collagen synthesis) and molecular
Taken together, the histological features, gene ex- (decrease in BSP and Osteocalcin expression) abnor-
pression abnormalities, and the decrease of Type I colla- malities are present in Rsk2- and Atf4-deficient mice;
gen production shared by Rsk2-deficient, Atf4-deficient, fourth, Rsk2/; Atf4/ mice have low bone mass phe-
and Rsk2/; Atf4/ mice corroborate the lack of ATF4 notype similar to the one of Rsk2-deficient mice.
phosphorylation in Rsk2-deficient osteoblasts pre- DNA cotransfection assays showed that RSK2 phos-
sented in Figure 2 and support the hypothesis that RSK2 phorylation modulates ATF4 transactivation function. In-
and ATF4 act in a cascade to control osteoblast differen- deed, a constitutively active form of RSK2 increased
tiation and function. Osteocalcin promoter activity through an ATF4 binding
The identification of Osteocalcin as an ATF4 target site. Additionally, this constitutively active form of RSK2
gene in osteoblasts allowed us to ask whether phos-
enhanced the transcription function of wt ATF4 but not
phorylation by RSK2 affects ATF4’s transactivation abil-
of ATF4-S251A that cannot be phosphorylated by RSK2.
ity. Forced expression of a constitutively active form of
Atf4-deficient mice have a much more severe skeletal
RSK2 (RSK2-T707A) (Poteet-Smith et al., 1999) in COS
phenotype than Rsk2-deficient mice suggesting ATF4’scells increased the activity of pOG2-luc reporter (Figure
function is regulated by other modifications. This hy-7I). This effect of RSK2-T707A required an intact OSE1
pothesis is consistent with the existence of multipleelement, suggesting that phosphorylation of ATF4 by
phosphorylation sites in ATF4. Our results do not ex-RSK2 enhances its transactivation ability. Consistent
clude the possibility that other transcription factor(s)with this hypothesis RSK2-T707A nearly doubled the
may also serve as RSK2 substrate(s) in osteoblasts nortransactivation ability of wt ATF4 when using a reporter
do we rule out either that RSK2 may have other sub-construct containing six copies of OSE1 (p6OSE1-Luc);
strates in other organs such as brain where its inactiva-in contrast RSK2-T707A could not increase the activity
tion causes major phenotypic abnormalities.of ATF4-S251A, an ATF4 mutant that cannot be phos-
phorylated by RSK2 (Figure 7J).
ATF4 and Osteoblast BiologyDiscussion
ATF4 affects all aspects of osteoblast biology. In ab-
sence of ATF4, the appearance of bone trabeculae isThis study reveals that ATF4 is a major regulator of
delayed. This delay in osteogenesis suggests that ATF4osteoblast differentiation. ATF4 also affects, through a
is required to mediate some aspects of Runx2 osteo-posttranscriptional mechanism, synthesis of Type I col-
blast differentiation function. The near abolition of Atf4lagen, the main function of osteoblasts. The regulation
expression in Runx2-deficient bone and the presenceof osteoblast function by ATF4 indicates that besides
of a Runx2 binding site in Atf4 promoter are consistentdetermining factors such as Runx2 other transcription
with this hypothesis that can now be tested in vivo.factors are required for maintenance of the osteoblast
However, the observation that bone formation occurs,phenotype. Furthermore, by showing that phosphoryla-
albeit in a delayed and abnormal manner, in absence oftion by RSK2 affects ATF4 functions this study also
ATF4 indicates that ATF4 is at least partially dispensablesuggests a molecular explanation for the skeletal mani-
for differentiation of mesenchymal cells into osteoblasts.festations observed in CLS.
In contrast ATF4 plays a more permanent role in os-
teoblast terminal differentiation. In situ and NorthernCellular and Molecular Bases of RSK2 Function
blot analyses showed that in Atf4-deficient osteoblastsin Osteoblasts
Bsp and Osteocalcin expression were markedly reducedThe initial descriptions of CLS reported skeletal abnor-
during development and after birth. The identificationmalities including short stature, delayed bone age, de-
of Osteocalcin as an ATF4 target gene in osteoblastslayed closure of fontanelles, osteopenia, and digital
establishes that some ATF4 functions occur through adysmorphism (Coffin et al., 1966; Lowry et al., 1971;
transcriptional mechanism. It will be important now toTemtamy et al., 1975). We show here using Rsk2-defi-
identify other ATF4 target gene(s) regulating osteoblastcient mice that these abnormalities are due to a defect
differentiation to decipher how bone mass accrual isin osteoblast function. Based on in vitro kinase assays
several substrates have been proposed for RSK2 includ- determined postnatally.
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Morphological AnalysisATF4 Control of Bone Formation and Amino
Alcian blue/alizarin red staining of skeletal preparations were per-Acid Import
formed using standard protocols (McLeod, 1980). For histologicalATF4 also controls bone formation through a posttran-
analysis, skeletons were fixed in 4% paraformaldehyde (PFA). Mice
scriptional mechanism by regulating the most important were injected with calcein at six and two days prior to sacrifice.
function of osteoblasts: their ability to synthesize Type Lumbar vertebrae sections (7 	m) were stained with van Gieson
and von Kossa reagents. Histomorphometric analysis was per-I collagen, a protein accounting for 90% of the bone
formed using the OsteoMeasure Analysis System (Osteometrics,ECM protein content (Prockop and Kivirikko, 1995). This
Inc.) according to standard criteria (Parfitt et al., 1987). Alternatefunction of ATF4 is critical to explain the virtual absence
sections stained with 1% toluidine blue were used for quantifyingof bone trabeculae before and after birth in Atf4-defi-
osteoblast numbers.
cient mice.
Multiple lines of evidence established in recent years
Gene Expression
that ATF4 is an integral component of the pathway con- For Northern blot analysis, total RNA of indicated sources were
trolling amino acid import that protects against oxidative extracted with Trizol (Invitrogen) and hybridized with appropriate
probes. Gapdh or 18S were used as a loading control. For in situstress. This pathway is initiated by phosphorylation of
hybridization analyses, embryos and pups were fixed in 4% PFA,eukaryotic translation initiation factor 2 (eIF2) and ex-
embedded in parafilm, and sectioned at 5 	m. A 271 bp 5 untrans-pression of Atf4 is dependent on eIF2 phosphorylation
lated region of Atf4 and a 390 bp 5 untranslated and partial of coding(Harding et al., 2002). PERK is one kinase that phosphor-
region of Osterix were cloned by RT-PCR and used to generate [35S]-
ylates eIF2. Interestingly mice and human deficient in labeled antisense riboprobes, other probes have been described
PERK have the same abnormal thinning of bone trabecu- (Ducy et al., 1997). Nuclear extracts (NE) of calvarial osteoblasts or
ROS17/2.8 cells were incubated with labeled OSE1 probe at roomlae as the one observed in Atf4-deficient mice (Delepine
temperature (RT) for 5 min. All antibodies tested were purchasedet al., 2000; Harding et al., 2000; Zhang et al., 2002).
from Santa Cruz except ATF4-N which was raised against epitopeHowever, PERK deficiency affects other secretory cells
QETNKEPPQTVNPIGHLPES. ChIP was performed according toleading for instance to exocrine and endocrine pancreas
manufacturer’s instruction (Upstate) using primary osteoblasts of
failure (Harding et al., 2001). That this is not the case in indicated genotypes. PCR primer sequences are available upon
Atf4-deficient mice reveals a functional specificity of request. COS cells were plated at 5  104/well in 12-well plates
and transfected with 0.5 	g of pOG2-luc and 0.05 	g of RSV--galATF4 in osteoblasts.
reporter vectors together with 0.5 	g of each expression plasmids
unless otherwise indicated. Luciferase and -galactosidase assays
Determining and Maintenance Factors were performed using standard procedures. Data represent ratios
of luciferase/-galactosidase activity.in Osteoblast Biology
A notion emerging from this and other studies is that
Protein Chemistrythere are two types of regulatory molecules at work
NE (500 	g) from calvarial osteoblasts or ROS 17/2.8 osteoblasticin osteoblasts. The first group comprises determining
cells were diluted with RIPA buffer (50 mM Tris-Cl, [pH 7.6], 150factors (Runx2 and Osterix) that are necessary and/or
mM NaCl, 1% NP-40, 0.5% Na-deoxycholate, and 0.1% SDS) andsufficient for the differentiation of osteochondroprogeni-
incubated at 4
C for 1 hr (h) with RSK2 or ATF4 antibody (Santa
tor cells into osteoblasts. To date, the thrust of their Cruz) in the presence of protease inhibitors. Protein G Sepharose (20
function appeared to be at this initial stage of differentia- 	l) (Amersham Pharmacia) was added for another hour. Sepharose
beads were washed four times and precipitated proteins resolvedtion. A second group of molecules includes LRP5 (Gong
by 10% SDS-PAGE followed by Western blot using ATF4 and RSK2et al., 2001; Kato et al., 2002) and ATF4. These molecules
antibodies. Total nuclear proteins (25 	g) were treated with 20 U ofare required to maintain the normal phenotype of osteo-
calf intestine alkaline phosphatase (Amersham Pharmacia) at RT forblasts including their ability to synthesize bone ECM
30 min, separated on a 10% SDS-PAGE followed by Western blot
proteins. Although this distinction may not be absolute, analysis using anti-ATF4 antibody. In vitro kinase assays using ac-
it provides a useful molecular framework to understand tive forms of mouse RSK2 (Upstate) were performed as follows.
GST or His-tagged recombinant proteins were expressed in bacteriahow osteoblast differentiation and ultimately function is
and purified according to standard protocols. Kinase reactions werecontrolled in vertebrates. This should also be useful to
performed at RT for ten min in the presence of [33P]-ATP, phosphor-uncover genetic pathways linking osteoblast differentia-
ylated products were resolved on a 10% SDS-PAGE before detec-tion and osteoblast function.
tion by autoradiography. Mutagenesis of ATF4 was performed using
a mutagenesis kit (Stratagene) following the manufacturer’s instruc-
tions. Integrity of all constructs was confirmed by DNA sequencing.Experimental Procedures
Phospho-ATF4 antibody was generated against synthetic peptide
NLPSPGGSRGSPPK in which the underlined serine was phosphory-Mutant Mice
Rsk2-deficient mice were generated using a targeting vector con- lated. Primary osteoblasts were labeled with 1 mCi/ml [32P]-ortho-
phosphate (Perkin Elmer) for eight hr in DMEM (phosphate free;taining a neomycin resistant (NeoR) gene and 3 stop codons in three
different frames at the end of the coding sequence inserted into Invitrogen) supplemented with 10% dialyzed FBS. ATF4 was immu-
noprecipitated using equal number of cpm for wt or Rsk2-deficientexon 2. Additionally, one loxP site at either ends of NeoR (see Figure
1B) was present. The NeoR was flanked by a 2 kb and 9 kb Rsk2 NE, separated by SDS-PAGE, membrane transferred, and visualized
by autoradiography. Prior to 12-o-tetradecanoyl phorbol-13-acetategenomic DNA at its 5 and 3 end, respectively. The linearized con-
struct was electroporated into 129SvJ embryonic stem (ES) cells, (TPA) treatment, 90% confluent wt, and Rsk2-deficient osteoblasts
were grown in -MEM containing 0.1% FCS 16 hr, TPA was addedtargeted ES cell clones identified by Southern blot were injected
into C57BL/6J blastocysts. NeoR was removed by crossing mutant for 15 min. For collagen synthesis wt, Atf4-, and Rsk2-deficient
osteoblasts were labeled with 50 	Ci/ml of [35S] methionine andmice with CMV-Cre transgenic mice. Primer sequences used for
genotyping of Rsk2-deficient mice are available upon request. Gen- cysteine mix (Amersham Pharmacia) for 12 hr in DMEM (methionine
and cysteine free; Invitrogen) supplemented with 2% dialyzed FBS,eration of Atf4-deficient mice has been described (Masuoka and
Townes, 2002). Six to twelve animals of each genotype were ana- 2 mM L-glutamine, 55 	M -mercaptoethanol, with or without
nonessential amino acid mix. Cells were homogenized, procollagenlyzed for all studies, statistical significance was assessed by Stu-
dent’s t test. Error bars represent standard errors of the means (SEM). digested to collagen with 50 	g/ml of pepsin, and Type I collagen
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precipitated (0.7 M NaCl), and resolved by 7% SDS-PAGE containing Harding, H.P., Zhang, Y., Bertolotti, A., Zeng, H., and Ron, D. (2000).
Perk is essential for translational regulation and cell survival during2 M urea as described (Bonadio et al., 1985).
the unfolded protein response. Mol. Cell 5, 897–904.
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